The dark side of nurse-manager leadership: toxic leadership behaviours, adverse-event reporting, and care quality-an interpretive descriptive study. [PDF]
Alshmemri M.
europepmc +1 more source
Location‐Specific Hematoma Volume Predicts Early Neurological Deterioration in Supratentorial ICH
ABSTRACT Objective Early neurological deterioration (END) adversely affects outcomes in patients with intracerebral hemorrhage (ICH). This study aimed to determine the location‐specific hematoma volumes for END in supratentorial ICH patients. Methods We retrospectively analyzed supratentorial ICH patients presenting from two prospective cohorts.
Zuoqiao Li +10 more
wiley +1 more source
An exploratory study of recognition behaviors practiced by mid-level nurse managers and perceived by mid-level staff nurses. [PDF]
Saito Y, Koyanagi H, Mano K, Murayama R.
europepmc +1 more source
ABSTRACT Objective To explore how cerebral hypoxia and Normal‐Appearing White Matter (NAWM) integrity affect MS lesion burden and clinical course. Methods Seventy‐nine MS patients, including 13 clinically isolated syndrome (CIS) patients and 66 relapsing–remitting multiple sclerosis (RRMS) patients, and 44 healthy controls (HCs) were recruited from ...
Xinli Wang +8 more
wiley +1 more source
Report on the 2025 DICOM WSI Connectathon. [PDF]
Clunie DA +34 more
europepmc +1 more source
Sex Representation in US Stroke Clinical Trials: A Decade of Trends and Challenges
ABSTRACT Objective Stroke remains a major cause of disability and mortality in the US, with significant sex‐based disparities, and females remain underrepresented in stroke clinical trials. We aimed to examine sex representation in US‐based stroke clinical trials, identify trial characteristics associated with higher female enrollment (≥ 50%), and ...
Chaitali Dagli +5 more
wiley +1 more source
Lessons learned from three approaches to digital pathology system validation at a large academic medical institution. [PDF]
Krishnan T +5 more
europepmc +1 more source
ABSTRACT Objective Onasemnogene abeparvovec (OA) is an AAV9‐based gene therapy for spinal muscular atrophy type I (SMA I). Real‐world outcomes show increased response variability compared to clinical trials, and follow‐up data beyond 12–18 months are limited.
Marika Pane +43 more
wiley +1 more source
The Effect of Nursing Practice Environment, Individual and Occupational Characteristics on Nurses' Attitudes Towards Medical Error: A Cross-Sectional Study. [PDF]
Polat Ş +3 more
europepmc +1 more source

